Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut-derived incretin hormones, known to stimulate insulin secretion for glycemic control, and in the case of GLP-1, also recognized to promote satiety, which has led to the development of a GLP-1 receptor (GLP-1R) agonist (GLP-1RA) as an obesity therapy1. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.